To view this page ensure that Adobe Flash Player version 9.0.0 or greater is installed, and Javascript is enabled.

Get Adobe Flash player

VIAGRA is indicated for the treatment of erectile dysfunction (ED).

IMPORTANT SAFETY INFORMATION

  • Nitrates: The use of VIAGRA and organic nitrates in any form, at any time, is contraindicated.
  • Cardiovascular: Before treating ED, physicians should consider the impact of resuming sexual activity and the mild and transient vasodilatory effects of VIAGRA on blood pressure. Physicians should carefully consider whether patients with underlying cardiovascular disease or other more unusual conditions could be adversely affected by vasodilatory effects, especially in combination with sexual activity.
  • Prolonged Erection: As there have been infrequent reports of prolonged erections lasting more than 4 hours or priapism with all ED treatments in this drug class, patients should be advised to seek immediate medical attention should these occur. Erections lasting longer than 6 hours can result in penile tissue damage and long-term loss of potency.
  • Specific Populations: Use a starting dose of 25 mg for patients who may have increased plasma levels
    (age >65, hepatic impairment, severe renal impairment, and concomitant use of potent CYP450 3A4 inhibitors). Patients taking ritonavir should not exceed 25 mg in a 48-hour period.
    Patients with the following characteristics (recent serious cardiovascular events, hypotension or uncontrolled hypertension, or retinitis pigmentosa) did not participate in pre-approval clinical trials. In these patients, physicians should prescribe VIAGRA with caution.
  • Vision/Hearing: Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely post-marketing in temporal association with the use of PDE5 inhibitors, including VIAGRA. Physicians should advise patients to stop use of PDE5 inhibitors, including VIAGRA, and seek medical attention in the event of sudden loss of vision.
    Sudden decrease or loss of hearing has been reported in temporal association with the intake of PDE5 inhibitors, including VIAGRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Physicians should advise patients to stop taking PDE5 inhibitors, including VIAGRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
  • Potential Drug Interactions: In a controlled interaction study of VIAGRA and amlodipine, the mean additional reduction in supine blood pressure was 8 mm Hg systolic and 7 mm Hg diastolic.
    Physicians should advise patients of the potential for PDE5 inhibitors, including VIAGRA, to augment the blood pressure lowering effect of alpha blockers and anti-hypertensive medications. In some patients concomitant administration of a PDE5 inhibitor and alpha blocker may lead to symptomatic hypotension. Patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at the lowest dose (25 mg).
    Physicians should inform patients not to take VIAGRA with other PDE5 inhibitors, including REVATIO, as the safety and efficacy in these combinations have not been studied.
  • Sexually Transmitted Diseases: Use of VIAGRA offers no protection against sexually transmitted diseases, including the human immunodeficiency virus (HIV); therefore, physicians should consider counseling their patients about protective measures.
  • Adverse Reactions: The most common side effects of VIAGRA were headache (16%), flushing (10%), and dyspepsia (7%). Adverse events, including visual effects (3%), were generally transient and mild to moderate.

Please scroll for Important Safety Information and Indication

IMPORTANT SAFETY INFORMATION

  • Nitrates: The use of VIAGRA and organic nitrates in any form, at any time, is contraindicated.
  • Cardiovascular: Before treating ED, physicians should consider the impact of resuming sexual activity and the mild and transient vasodilatory effects of VIAGRA on blood pressure. Physicians should carefully consider whether patients with underlying cardiovascular disease or other more unusual conditions could be adversely affected by vasodilatory effects, especially in combination with sexual activity.
  • Prolonged Erection: As there have been infrequent reports of prolonged erections lasting more than 4 hours or priapism with all ED treatments in this drug class, patients should be advised to seek immediate medical attention should these occur. Erections lasting longer than 6 hours can result in penile tissue damage and long-term loss of potency.
  • Specific Populations: Use a starting dose of 25 mg for patients who may have increased plasma levels
    (age >65, hepatic impairment, severe renal impairment, and concomitant use of potent CYP450 3A4 inhibitors). Patients taking ritonavir should not exceed 25 mg in a 48-hour period.
    Patients with the following characteristics (recent serious cardiovascular events, hypotension or uncontrolled hypertension, or retinitis pigmentosa) did not participate in pre-approval clinical trials. In these patients, physicians should prescribe VIAGRA with caution.
  • Vision/Hearing: Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely post-marketing in temporal association with the use of PDE5 inhibitors, including VIAGRA. Physicians should advise patients to stop use of PDE5 inhibitors, including VIAGRA, and seek medical attention in the event of sudden loss of vision.
    Sudden decrease or loss of hearing has been reported in temporal association with the intake of PDE5 inhibitors, including VIAGRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Physicians should advise patients to stop taking PDE5 inhibitors, including VIAGRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
  • Potential Drug Interactions: In a controlled interaction study of VIAGRA and amlodipine, the mean additional reduction in supine blood pressure was 8 mm Hg systolic and 7 mm Hg diastolic.
    Physicians should advise patients of the potential for PDE5 inhibitors, including VIAGRA, to augment the blood pressure lowering effect of alpha blockers and anti-hypertensive medications. In some patients concomitant administration of a PDE5 inhibitor and alpha blocker may lead to symptomatic hypotension. Patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at the lowest dose (25 mg).
    Physicians should inform patients not to take VIAGRA with other PDE5 inhibitors, including REVATIO, as the safety and efficacy in these combinations have not been studied.
  • Sexually Transmitted Diseases: Use of VIAGRA offers no protection against sexually transmitted diseases, including the human immunodeficiency virus (HIV); therefore, physicians should consider counseling their patients about protective measures.
  • Adverse Reactions: The most common side effects of VIAGRA were headache (16%), flushing (10%), and dyspepsia (7%). Adverse events, including visual effects (3%), were generally transient and mild to moderate.

INDICATION

VIAGRA is indicated for the treatment of erectile dysfunction (ED).